C.C. VS. DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES (DIVISION OF MENTAL HEALTH AND ADDICTION SERVICES) (RECORD IMPOUNDED) ( 2020 )


Menu:
  •                                       RECORD IMPOUNDED
    NOT FOR PUBLICATION WITHOUT THE
    APPROVAL OF THE APPELLATE DIVISION
    This opinion shall not "constitute precedent or be binding upon any court." Although it is posted on the
    internet, this opinion is binding only on the parties in the case and its use in other cases is limited. R. 1:36-3.
    SUPERIOR COURT OF NEW JERSEY
    APPELLATE DIVISION
    DOCKET NO. A-2736-18T4
    C.C.,
    Appellant,
    v.
    DIVISION OF MENTAL HEALTH
    AND ADDICTION SERVICES,
    Respondent.
    ______________________________
    Submitted January 8, 2020 – Decided January 28, 2020
    Before Judges Haas and Mayer.
    On appeal from the New Jersey Department of Human
    Services, Division of Mental Health and Addiction
    Services.
    C.C., appellant pro se.
    Gurbir S. Grewal, Attorney General, attorney for
    respondent (Melissa H. Raksa, Assistant Attorney
    General, of counsel; Tanjika Nicole Williams-Parks,
    Deputy Attorney General, on the brief).
    PER CURIAM
    C.C.1 appeals a final decision issued by the Medical Director of Trenton
    Psychiatric Hospital (TPH) authorizing administration of psychotropic
    medication without her consent. We affirm.
    C.C. was involuntarily committed to the care of TPH after being
    diagnosed with schizophrenia. On January 30, 2019, Dr. Mohammad Bari,
    C.C.'s     prescribing   psychiatrist,   completed   an   Involuntary   Medication
    Administration Report (IMAR), recommending involuntary administration of
    Geodon® and Ativan ® to treat C.C.'s schizophrenia. He reported C.C. was
    "refusing medication intermittently. She [was] delusional, hostile and ha[d]
    been threatening staff [and] accusing [them of] rape." According to the IMAR,
    C.C. also threatened to shoot TPH staff. Although C.C. was counseled regarding
    the benefits associated with the medications, Dr. Bari reported she was n ot
    receptive to such treatment. While C.C. responded positively on Geodon ®, she
    subsequently refused to take that medication, claiming she was "highly allergic,"
    and the forced administration of Geodon ® made "[her] feel like [she was] dying."
    In accordance with protocols developed by the State Department of
    Health, Division of Mental Health and Addiction Services (DMHAS), TPH's
    Medical Director signed the IMAR and scheduled a panel review hearing. A
    1
    We use initials to protect appellant's privacy. R. 1:38-3(f)(2).
    A-2736-18T4
    2
    copy of the IMAR was hand-delivered to C.C. on February 1, 2019. A hearing
    before a panel of three non-treating medical professionals was held on February
    5, 2019. C.C. received notice of the hearing, and a Client Services Advocate
    was appointed to assist her through the process.
    At the panel hearing, TPH presented testimony from C.C.'s prescribing
    doctor who stated C.C. "expressed delusions she [was] being raped by staff and
    patients causing her to accuse and threaten others. This cause[d] her to endanger
    herself (by becoming a target for attack) and others." Without the medication,
    the prescriber testified C.C. would likely cause serious harm to herself and
    others.
    C.C. testified at the hearing. She claimed she didn't "need any medication
    but in order to comply and get out of [TPH she would] take Abilify or
    [Z]yprexa." According to C.C., "Clozaril and Geodon cause[d her] to have side
    effects of dizziness and pal[l]or and cause[d her] to stay sedated all day."
    The panel approved the involuntary administration of medication,
    concluding C.C. "achieved a higher level of care (due to improved behavioral
    control)" "[w]hen compliant with medication."        The panel found sufficient
    evidence to medicate C.C. without her consent "to target symptoms causing her
    to endanger herself and others," authorized alternative treatment with Abilify ®
    A-2736-18T4
    3
    or Zyprexa ®, and ordered monitoring for any side effects associated with
    Geodon®.
    At the conclusion of the hearing, C.C. received the panel's decision. C.C.
    timely appealed the panel's determination to TPH's Medical Director. The
    Medical Director conducted a review and upheld the panel's February 5, 2019
    decision, finding "[t]he recommended treatment is within the standard of care."
    In accordance with the February 5, 2019 decision, involuntary treatment
    of C.C. was authorized for ninety days with periodic reviews every fourteen
    days. During the periodic reviews of C.C.'s treatment progress, TPH staff
    reported C.C. continued to refuse consent to medication and took the medication
    intermittently. TPH staff and the Client Services Advocate assigned to C.C.
    reported she remained delusional, paranoid, accusatory, and threatening. The
    Client Service Advocate certified the administration of C.C.'s involuntary
    medication complied with DMHAS policy.
    C.C. filed an appeal February 27, 2019. On appeal, C.C. argues she does
    not have any mental illness requiring her to be medicated. She also contends
    she is not a danger to herself or others.
    Our scope of review of an administrative agency's final determination is
    limited. In re Herrmann, 
    192 N.J. 19
    , 27 (2007). "[A] 'strong presumption of
    A-2736-18T4
    4
    reasonableness attaches'" to the agency's decision. In re Carroll, 
    339 N.J. Super. 429
    , 437 (App. Div. 2001) (quoting In re Vey, 
    272 N.J. Super. 199
    , 205 (App.
    Div. 1993)). We will "not disturb an administrative agency's determinations or
    findings unless there is a clear showing that (1) the agency did not follow the
    law; (2) the decision was arbitrary, capricious, or unreasonable; or (3) the
    decision was not supported by substantial evidence." In re Virtua-West Jersey
    Hosp. Voorhees for a Certificate of Need, 
    194 N.J. 413
    , 422 (2008). The
    appellant bears the burden to demonstrate grounds for reversal. McGowan v.
    N.J. State Parole Bd., 
    347 N.J. Super. 544
    , 563 (App. Div. 2002).
    Applying this standard, we conclude TPH's decision to involuntarily
    medicate C.C. was not arbitrary, capricious, or unreasonable. The decision by
    TPH's Medical Director is supported by sufficient credible and unrefuted
    evidence.   In addition, TPH followed the DMHAS involuntary medication
    policies and procedures. 2    The decision was based on the judgment of
    2
    The polices and procedures are contained in the agency's administrative
    bulletins AB 5:04 (addressing informed consent), AB 5:04A (addressing the
    emergency administration of psychotropic medications without consent); and
    AB 5:04B (addressing the non-emergent administration of psychotropic
    medications without consent). See State of N.J. Dep't of Human Servs., Div. of
    Mental Health & Addiction Servs. Admin. Bulletins 5:04, 5:04A, 5:04B (June
    4, 2012) https://www.state.nj.us/humanservices/dmhas/regulations/bulletins.
    A-2736-18T4
    5
    independent clinicians following a hearing and subsequent administrative
    appeal.
    Affirmed.
    A-2736-18T4
    6
    

Document Info

Docket Number: A-2736-18T4

Filed Date: 1/28/2020

Precedential Status: Non-Precedential

Modified Date: 1/28/2020